Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Tommaso Stefanelli"'
Autor:
Franco Locatelli, Bulent Antmen, Hyoung Jin Kang, Katsuyoshi Koh, Yoshiyuki Takahashi, Alphan Kupesiz, Maria Gabriela Matos, Donna Wall, Sunil Bhat, Ho Joon Im, Tayfun Gungor, Meng-Yao Lu, Tommaso Stefanelli, Christine Rosko, Annie St. Pierre, Karin Burock, Cristina Diaz-De-Heredia
Publikováno v:
HemaSphere, Vol 7, p e54405ff (2023)
Externí odkaz:
https://doaj.org/article/a8dc3d936beb42a9ae950ba84c082f88
Autor:
Maria A. Pantaleo, Michael C. Heinrich, Antoine Italiano, Claudia Valverde, Patrick Schöffski, Giovanni Grignani, Anna K. L. Reyners, Sebastian Bauer, Peter Reichardt, Daniel Stark, Ghimja Berhanu, Ulrike Brandt, Tommaso Stefanelli, Hans Gelderblom
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-8 (2022)
Abstract Background Acquired resistance to approved tyrosine kinase inhibitors limits their clinical use in patients with gastrointestinal stromal tumor (GIST). This study investigated the safety, tolerability and efficacy of alpelisib, a phosphatidy
Externí odkaz:
https://doaj.org/article/2f1e77cece464909a2d9a3ecf8c75f78
Autor:
Claire Harrison, Florian H. Heidel, Alessandro M. Vannucchi, Jean-Jacques Kiladjian, Amjad Hayat, Francesco Passamonti, Eibhlin Conneally, Thomas Kindler, Bruno Martino, Daniel B. Lipka, Tommaso Stefanelli, Pantelia Roussou, Davide Germano, Jacqueline Ewan, Vincent Ribrag
Publikováno v:
HemaSphere, Vol 6, Iss 8, p e757 (2022)
Externí odkaz:
https://doaj.org/article/e4ad9ac6fbc047909aa7e4c5b130001e
Publikováno v:
Blood. 140:10521-10522
Autor:
Maanasa Gowda, Franco Locatelli, Tommaso Stefanelli, Norbert Hollaender, Shahrukh K. Hashmi, Robert Zeiser, Mary E.D. Flowers, Fitzroy Dawkins, Ronjon Chakraverty, Stephanie J. Lee, Nicola Polverelli, Takanori Teshima, Ron Ram
Publikováno v:
Blood. 136:22-24
BACKGROUND Standard first-line treatment of cGVHD includes systemic corticosteroids; however, about 50% of patients (pts) are steroid refractory or dependent (SR/D) and require additional treatment. The best second-line therapy option has not yet bee
Autor:
Franco Locatelli, Tommaso Stefanelli, Valkal Bhatt, Shashikant Apte, Nada Hamad, Stephanie J. Lee, Francesca Bonifazi, Takanori Teshima, Jackie Han, Kentaro Fukushima, Maanasa Gowda, Ivan S. Moiseev, Juan Carlos Vallejo Llamas, Joseph Pidala, Francis Ayuk, Robert Zeiser, Tsila Zuckerman, Mike Zuurman
Publikováno v:
Blood. 138:3909-3909
BACKGROUND Approximately 50% of patients (pts) who receive initial cGVHD therapy are steroid refractory or dependent (SR/D); standard second-line therapy has yet to be established. Quality of life (QOL) in these pts is poor and worsens with disease s
Autor:
Norbert Hollaender, Ronjon Chakraverty, Maanasa Gowda, Franco Locatelli, Stephanie J. Lee, Ron Ram, Tommaso Stefanelli, Shahrukh K. Hashmi, Takanori Teshima, Peter Langmuir, Nicola Polverelli, Robert Zeiser
Publikováno v:
Web of Science
Autor:
Elena Litvinskaya, Janusz Kloczko, Tadeusz Robak, Ewa Lech-Marańda, Justyna Rybka, Grygoriy Rekhtman, Sebastian Grosicki, Wojciech Homenda, Javier Loscertales, Tommaso Stefanelli, Iryna Kriachok, Ghislaine Vincent, Kanakasetty Govind Babu, Jerzy Z. Blonski, Hiya Banerjee
Publikováno v:
Leukemialymphoma. 61(7)
Anti-CD20 monoclonal antibodies (mAbs) in combination with chemotherapies have changed the treatment landscape for chronic lymphocytic leukemia (CLL) [1]. Rituximab added to fludarabine with cyclop...
Autor:
Udvardy, Miklos, Vladimir, Strugov, Catharina, Lewerin, Sebastian, Grosicki, Grzegorz, Mazur, Michael, Steurer, Marco, Montillo, Irina, Kryachok, Jan M, Middeke, Grygoriy, Rekhtman, Tommaso, Stefanelli, Ghislaine, Vincent, Sameera, Govindaraju, Anders, Österborg
Publikováno v:
British journal of haematologyReferences. 189(4)
In 2014, an interim analysis of a phase 3 study was performed to evaluate the effectiveness of ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukaemia (BFR CLL) as compared to physician's choice. The five-year follow-up
Autor:
Marinus H. J. van Oers, Sebastian Grosicki, Lukas Smolej, Tommaso Stefanelli, Mark-David Levin, Jaclyn Davis, Fritz Offner, Mario Petrini, Petra Hoever, Hiya Banerjee, Christian H. Geisler
Publikováno v:
BLOOD CANCER JOURNAL
Blood Cancer Journal, Vol 9, Iss 12, Pp 1-9 (2019)
Blood cancer journal, 9(12):98. Nature Publishing Group
Blood Cancer Journal
Blood Cancer Journal, Vol 9, Iss 12, Pp 1-9 (2019)
Blood cancer journal, 9(12):98. Nature Publishing Group
Blood Cancer Journal
We report the final analysis of the PROLONG study on ofatumumab maintenance in relapsed chronic lymphocytic leukemia (CLL). In all, 480 patients with CLL in complete or partial remission after second- or third-line treatment were randomized 1:1 to of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f29c71ed30d2020e9002d061532af293
https://biblio.ugent.be/publication/8647119
https://biblio.ugent.be/publication/8647119